Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

January 31, 2011 09:00 ET

Theralase Receives Approval for Product Sales Into Europe

TORONTO, ONTARIO--(Marketwire - Jan. 31, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) is pleased to announce that it has been granted notified body approval to place the CE mark on its TLC-1000 series of products, clearing the way for sale of its laser products throughout all 30 member states of the European Union (EU).

CE approval is a mandatory approval stage in the sale of products to European Union (EU) countries. It serves as a declaration that the product meets EU consumer safety, health and environmental requirements.

"Achieving CE approval allows Theralase another opportunity to expand the sale of our medical lasers internationally", stated Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. "By possessing CE approval, in addition to our Health Canada, FDA and certain Latin American and Asian approvals, we are now able to sell our medical lasers to over 63% of the world market (as measured by GDP). This presents a great opportunity for Theralase to expand our revenue generation capability beyond our present markets."

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information